Clinical Outcomes and Associated Factors of Parainfluenza Virus Infection in Pediatric Immunocompromised Hosts

Background Parainfluenza virus (PIV) is an important cause of respiratory tract infection in immunocompromised children, yet contemporary data across diverse pediatric populations with impaired immunity remain limited. We aimed to describe the epidemiology, clinical outcomes, and factors associated with PIV infection in this population. Methods We conducted a retrospective cohort study of immunocompromised children and young adults (≤ 25 years) with laboratory-confirmed PIV infection at St. Jude Children’s Research Hospital between 2014 and 2024. Logistic regression was applied to identify factors associated with clinical outcomes, including hospitalization, oxygen requirement, ICU admission, and composite lower respiratory tract infection (LRTI), defined as LRTI at presentation or progression from URTI to LRTI within 28 days of PIV onset. Results A total of 476 patients were included, with a median age of 5.3 years (interquartile range, 2.8-10.5). Most patients (287/476) had hematologic malignancies, and 18% (87/476) had undergone hematopoietic cell transplantation (HCT) or chimeric antigen receptor T-cell (CAR-T) therapy. PIV-3 was the predominant subtype (53%). Overall, 228 patients (48%) required hospitalization, 61 (13%) experienced composite LRTI, 45 (9%) required supplemental oxygen, 32 (7%) required ICU admission, 95/464 (20%) experienced prolonged viral shedding, and 62 (13%) had delay/modification of planned therapy. Three patients (1%) died from PIV-attributable complications within 90 days. Composite LRTI was associated with adverse clinical outcomes, including hospitalization, oxygen requirement, and ICU admission. Conclusions PIV remains an important cause of morbidity in pediatric immunocompromised hosts. Although PIV-attributable mortality was uncommon, respiratory complications, prolonged viral shedding, and interruptions in cancer-directed therapy were frequent. These findings describe factors associated with adverse outcomes and support closer clinical monitoring and continued development of preventive and therapeutic strategies.

Authors

Institutions

Publication Details

Journal
Open Forum Infectious Diseases
Published
2026-11-21
DOI
https://doi.org/10.1093/ofid/ofag777
Primary Topic
Respiratory viral infections research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Clinical Outcomes and Associated Factors of Parainfluenza Virus Infection in Pediatric Immunocompromised Hosts

Ashleigh Gowen, Tina Culley, Randall T. Hayden, Kim Allison et al.
Open Forum Infectious Diseases
Respiratory viral infections research
article

Clinical Outcomes and Associated Factors of Parainfluenza Virus Infection in Pediatric Immunocompromised Hosts

Ashleigh Gowen, Tina Culley, Randall T. Hayden, Kim Allison, Amanda Cole, Ronald H. Dallas, Jose Amadeo A Ferrolino, Diego R. Hijano, Pamela Merritt, Gabriela Maria Marón, Ali Y Suliman, Linlin Gu, Sapna A Pardasani, Megan Peterson, Amber Davis
article en

Abstract

Background Parainfluenza virus (PIV) is an important cause of respiratory tract infection in immunocompromised children, yet contemporary data across diverse pediatric populations with impaired immunity remain limited. We aimed to describe the epidemiology, clinical outcomes, and factors associated with PIV infection in this population. Methods We conducted a retrospective cohort study of immunocompromised children and young adults (≤ 25 years) with laboratory-confirmed PIV infection at St. Jude Children’s Research Hospital between 2014 and 2024. Logistic regression was applied to identify factors associated with clinical outcomes, including hospitalization, oxygen requirement, ICU admission, and composite lower respiratory tract infection (LRTI), defined as LRTI at presentation or progression from URTI to LRTI within 28 days of PIV onset. Results A total of 476 patients were included, with a median age of 5.3 years (interquartile range, 2.8-10.5). Most patients (287/476) had hematologic malignancies, and 18% (87/476) had undergone hematopoietic cell transplantation (HCT) or chimeric antigen receptor T-cell (CAR-T) therapy. PIV-3 was the predominant subtype (53%). Overall, 228 patients (48%) required hospitalization, 61 (13%) experienced composite LRTI, 45 (9%) required supplemental oxygen, 32 (7%) required ICU admission, 95/464 (20%) experienced prolonged viral shedding, and 62 (13%) had delay/modification of planned therapy. Three patients (1%) died from PIV-attributable complications within 90 days. Composite LRTI was associated with adverse clinical outcomes, including hospitalization, oxygen requirement, and ICU admission. Conclusions PIV remains an important cause of morbidity in pediatric immunocompromised hosts. Although PIV-attributable mortality was uncommon, respiratory complications, prolonged viral shedding, and interruptions in cancer-directed therapy were frequent. These findings describe factors associated with adverse outcomes and support closer clinical monitoring and continued development of preventive and therapeutic strategies.

Open Forum Infectious Diseases
St. Jude Children's Research Hospital (US), University of Tennessee Health Science Center (US)
Respiratory viral infections research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon